Alcea (Acino Rus)

Alcea is a pharmaceutical company headquartered in Moscow. Previously part of Acino International, since November 2023 it has been operating in Russia as an independent business.

History

2023: Separate into an independent business and start working under the Alcea brand

On November 20, 2023, the Russian division of the international pharmaceutical group Acino International informed Zdrav.Expert about the separation into an independent business and the start of work under the Alcea brand.

The company has developed in Russia since 2015 under the Acino brand. During this time, she managed to take a strong position in the market and form a portfolio of drugs and dietary supplements designed to support the health of women and men throughout her life, representatives of the company noted. According to them, at the time of launch under the name "Alcea," the company is in the top 3 pharmaceutical companies in the targeted category of women's health on the Russian market.

"Acino in Russia has shown dynamic growth in recent years. At the end of 2022, we became the fastest growing pharmaceutical company among the top 10 in the address market, - said the head of Altsey Denis Glyadyaev, who previously headed Acino Rus for more than 5 years. "As an independent company, we will continue to implement the existing growth strategy in order to meet the needs of Russian patients as well as possible."

According to Denis Glyadyaev, in the future of three to five years, Alcea plans to maintain double-digit growth indicators, using for this, first of all, the potential of its portfolio of high-quality medicines for women's and men's health. All Acino brands represented in Russia will remain in the portfolio of Alcea. Also, the changes will not affect the supply chains. The company will continue to introduce systemic innovations into its business processes and is ready for further progressive development.

Alcei's headquarters are located in Moscow, and it has about 200 employees who work in more than 50 cities in Russia. As of November 2023, the company's portfolio includes 21 brands in the categories of women's health, proctology and urology (among the most popular of them are Indinol Forto, Posterian, Neo-Penotran, Ferretab, Estrovel, Cervicon-DIM). Every month the company supplies its products to more than 50 thousand pharmacies throughout the country - it is predicted that by the end of 2023 shipments will amount to more than 5 million packages. According to the company, the increase in the purpose of Alcea products in the category of women's health amounted to 70% over the past three years. 80% of the products from Alcea's portfolio of own drugs are produced in Russia, which ensures reliable supplies and independence from imports.

Another important area that Alcea will continue to pay special attention to is the exchange of experience and knowledge with the medical and pharmaceutical communities. The company annually holds over 1.6 thousand educational events in more than 90 cities of Russia.

"Many of our drugs are indicated for the treatment of background precancerous diseases in women. Also in the portfolio there are drugs to support pregnancy. We are very glad to see that the results of our activities can give many women a chance to maintain reproductive health and endure a healthy child, "added Denis Glyadyaev. - As a self-contained company, we are going to focus even more efforts on bringing knowledge to the medical community. It is also a priority to raise public awareness in the prevention and treatment of diseases, since it is important for us to provide comprehensive support to people in matters of health care. "